Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes
Abstract
Type 2 diabetes (T2D) is a large and growing epidemic. Importantly, new technologies and pharmaceutical options are improving the management of T2D. Continuous glucose monitoring (CGM) systems have advanced glucose-sensing technology, which has made it easier for users to monitor their glucose levels. Glucagon-like peptide 1-based therapies and dual agonists have similarly revolutionized the treatment of T2D. In this article, we present four cases of individuals with T2D who, in collaboration with their healthcare provider, used the data from their CGM systems to inform therapy changes, including the initiation and titration of glucagon-like peptide 1-based therapies. Combined use of CGM systems and glucagon-like peptide 1-based therapies could improve people's diabetes as well as their overall health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.